Rockefeller Financial Services Inc. reduced its stake in shares of Celgene Corporation (NASDAQ:CELG) by 1.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,269 shares of the biopharmaceutical company’s stock after selling 130 shares during the period. Rockefeller Financial Services Inc.’s holdings in Celgene Corporation were worth $1,723,000 at the end of the most recent quarter.
Other large investors also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in Celgene Corporation by 2.3% in the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares during the period. Bank of New York Mellon Corp boosted its stake in Celgene Corporation by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after buying an additional 472,067 shares during the period. American Century Companies Inc. boosted its stake in Celgene Corporation by 4.4% in the first quarter. American Century Companies Inc. now owns 6,563,791 shares of the biopharmaceutical company’s stock valued at $816,733,000 after buying an additional 276,089 shares during the period. Norges Bank bought a new stake in Celgene Corporation during the fourth quarter valued at about $694,111,000. Finally, Pioneer Investment Management Inc. boosted its stake in Celgene Corporation by 15.7% in the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after buying an additional 710,584 shares during the period. 78.41% of the stock is owned by institutional investors.
Shares of Celgene Corporation (NASDAQ CELG) opened at 135.27 on Wednesday. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The stock has a market capitalization of $105.83 billion, a P/E ratio of 41.89 and a beta of 1.89. The company’s 50-day moving average is $133.32 and its 200-day moving average is $123.59.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The company had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. During the same quarter last year, the company earned $1.44 earnings per share. Celgene Corporation’s revenue for the quarter was up 18.7% on a year-over-year basis. On average, equities research analysts anticipate that Celgene Corporation will post $7.32 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Celgene Corporation (NASDAQ:CELG) Shares Sold by Rockefeller Financial Services Inc.” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://baseballnewssource.com/markets/rockefeller-financial-services-inc-has-1-72-million-position-in-celgene-corporation-nasdaqcelg-updated/1314009.html.
CELG has been the subject of several research reports. BTIG Research cut shares of Celgene Corporation from a “buy” rating to a “neutral” rating and boosted their price objective for the company from $96.93 to $131.70 in a research report on Friday, June 30th. Leerink Swann reissued an “outperform” rating and issued a $160.00 price objective (up from $150.00) on shares of Celgene Corporation in a research report on Friday, July 28th. Argus raised shares of Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price objective for the company from $96.93 to $160.00 in a research report on Monday, July 31st. Credit Suisse Group set a $148.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 6th. Finally, Cann reaffirmed a “buy” rating on shares of Celgene Corporation in a research report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have given a buy rating to the company. Celgene Corporation has a consensus rating of “Buy” and an average price target of $147.06.
In other news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $125.59, for a total transaction of $1,161,707.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rupert Vessey sold 4,785 shares of the stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the transaction, the insider now owns 4,004 shares of the company’s stock, valued at $481,200.72. The disclosure for this sale can be found here. Insiders sold 235,255 shares of company stock valued at $31,377,042 in the last ninety days. 0.95% of the stock is owned by corporate insiders.
Celgene Corporation Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with our FREE daily email newsletter.